PD-L1 expression in CAAs prevents anti-PD-L1 antibodies from activating important antitumor functions of CD8+ T lymphocytes, which results in BC resistance to anti-PD-L1 immunotherapy [141]. The gene discussed is CD274; the disease is breast cancer.